super responders to tirzepatide When Weight-Loss Drugs Don't Work Everyone wants to be a
Description
The limitation: less regulatory oversight compared to branded pharmaceuticals
External resources Triple-Hormone-Receptor Agonist Retatrutide for Obesity, Phase 2 Trial (NEJM) Tirzepatide Once Weekly for the Treatment of Obesity, SURMOUNT-1 (NEJM) Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease (Nature Medicine) In case I do not see you, good afternoon, good evening, and good night
Other GLP-1 receptor agonists include semaglutide (Wegovy for weight management, Ozempic for diabetes) and liraglutide (Saxenda for weight management, Victoza for diabetes), with semaglutide 2.4 mg demonstrating greater average weight loss than liraglutide 3.0 mg in clinical trials
Most med spas charge $1k or more per month, so this is extremely affordable in comparison
Note: results shown for four selected drugs Sources: IQVIA Integrated Insights Tracker: Obesity, UK report, Nov 2024
Gene Set Enrichment Analysis (GSEA) uncovered unique impacts of RETA on key biological processes
